Paul M. Silva - 05 May 2022 Form 4 Insider Report for Nurix Therapeutics, Inc. (NRIX)

Role
Director
Signature
/s/ Christine Ring, as Attorney-in-Fact for Paul M. Silva
Issuer symbol
NRIX
Transactions as of
05 May 2022
Net transactions value
$0
Form type
4
Filing time
06 May 2022, 17:44:38 UTC
Previous filing
01 Oct 2021
Next filing
04 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRIX Director Stock Option (right to buy) Award $0 +17,500 $0.000000 17,500 05 May 2022 Common Stock 17,500 $10.39 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 5, 2023, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.